CTI BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results
– VONJOTM Approved by FDA for the Treatment of Adult Myelofibrosis Patients with Myelofibrosis and Thrombocytopenia; Commercial Launch Underway – – $60 Million Payment from DRI... | March 31, 2022
United States Adamr Craig Securities Exchange Biopharma Corp Healthcare Trust Adult Myelofibrosis Patients
Source: marketscreener.com